CTLT (Catalent) Notes Receivable : $0 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Catalent Notes Receivable?

Catalent's Notes Receivable for the quarter that ended in Sep. 2024 was $0 Mil.

Catalent Notes Receivable Historical Data

The historical data trend for Catalent's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Notes Receivable Chart

Catalent Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Notes Receivable

Get a 7-Day Free Trial

Catalent Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Catalent Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Catalent Notes Receivable Related Terms

Thank you for viewing the detailed overview of Catalent's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Executives

Michelle R Ryan	director	214 PARK BLVD S, VENICE FL 34285
Joseph Anthony Ferraro	officer: SVP, General Counsel, CCO	56 EMILY ROAD, FAR HILLS FL 07931
David Mcerlane	officer: Group President, Biologics	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson	officer: VP, Chief Accounting Officer	CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lisa Evoli	officer: SVP, Chief HR Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Aristippos Gennadios	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli	officer: See remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Matti Masanovich	officer: SVP, Chief Financial Officer	COLLINS & AIKMAN CORPORATION, 250 STEPHENSON HIGHWAY, TROY MI 48083
Steven Barg	director	ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
John J Greisch	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Frank A Damelio	director	C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Jonathan Arnold	officer: President, Oral Drug Delivery	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven L Fasman	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873